Evidence map›Paper›PMID 41182487›Full record

ArticleAnnals of surgical oncology2026

Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma.

Hiroyuki Ishida, Salvador Rodriguez Franco, Oskar Franklin, Yuki Fujiwara, Andrii Khomiak, Nicole Baranda Balmaceda, Riccardo Pellegrini, Benedetto Mungo, Richard D Schulick, Marco Del Chiaro

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroyuki IshidaDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Salvador Rodriguez FrancoDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Oskar FranklinDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Yuki FujiwaraDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Andrii KhomiakDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Nicole Baranda BalmacedaDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Riccardo PellegriniDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Benedetto MungoDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Richard D SchulickDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Marco Del ChiaroDivision of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA. marco.delchiaro@cuanschutz.edu.

Funding

Region Västerbotten in Umeå, Sweden RV 967602The Royal Swedish Academy of Sciences LM2021-0010The Royal Swedish Academy of Sciences LM2023-0012The Swedish Society of Medicine SLS-934237
6 · The paper itself

Abstract

backgroundInvasive intraductal papillary mucinous neoplasms (I-IPMNs) are considered more indolent than conventional pancreatic ductal adenocarcinoma (PDAC). Although neoadjuvant therapy (NAT) is widely adopted in PDAC, its role in I-IPMN remains unclear. This study aimed to evaluate the impact of NAT on survival in I-IPMN compared with PDAC.

methodsThe study enrolled I-IPMN and PDAC patients undergoing resection at the University of Colorado Hospital between 2013 and 2023. Prognostic factors for overall survival (OS) were identified using Cox models. OS was compared between histology/NAT subgroups using the Kaplan-Meier method and the log-rank test, stratified by resectability.

resultsOf 500 patients (413 PDAC, 87 I-IPMN), 289 PDAC and 34 I-IPMN patients received NAT, and the I-IPMN patients showed slightly longer median OS than the PDAC patients (30.2 vs 28.1 months; p = 0.04). In the entire cohort, worse OS was associated with borderline resectable (BR)/locally advanced (LA) disease, elevated cancer antigen 19-9 (CA19-9), node-positive disease, lymphovascular invasion, perineural invasion, and absence of adjuvant therapy. In the resectable cohort (n = 311), NAT was associated with longer OS in PDAC (61.9 vs 34.2 months; p < 0.001), but not in I-IPMN (not reached vs 47.9 months; p = 0.74). Survival did not differ between NAT-treated resectable I-IPMN and PDAC (p = 0.95). In the BR/LA cohort treated with NAT (n = 183), OS was similar between I-IPMN and PDAC (17.1 vs 22.0 months; p = 0.69).

conclusionsIn resectable I-IPMN, NAT was not associated with improved survival. Comparable survival between NAT-treated BR/LA I-IPMN and PDAC suggests a need for further research on treatment outcomes.

Indexed as

Adenocarcinoma, MucinousCarcinoma, Pancreatic DuctalCarcinoma, PapillaryNeoadjuvant TherapyPancreatic Intraductal NeoplasmsPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessPancreatectomyCA19-9ChemotherapyIntraductal papillary mucinous neoplasmNeoadjuvant therapyPancreatic cancer

Identifiers

PMID41182487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.